FDA Brief

Warning letters Drugs

FDA warning letter to

Pharmacy Plus, Inc., dba Vital Care Compounder

High riskIssued Jun 6, 2023Posted Jun 13, 2023Division of Pharmaceutical Quality Operations II

FDA warned Pharmacy Plus (Vital Care Compounder) that its sterile compounded drugs were made under insanitary conditions, risking contamination.

What happened

FDA inspected the Hattiesburg, MS facility from October 3 to October 13, 2022, and found serious deficiencies in sterile drug production. FDA issued a Form FDA 483 on October 13, 2022. The firm had recalled sterile drugs within expiry on October 7, 2022, because it lacked sterility assurance.

What FDA found

  1. FDA found microbial contamination in the sterile work area (ISO 5) and the firm did not take adequate corrective action.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The laminar airflow hood had dirty, hard-to-clean, particle-generating surfaces, and staff used non-sterile pads and wipes in the sterile work area.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. An operator used a non-sterile tool on and manually touched the inside of a sterile drug container or closure.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. An operator left the sterile work area with gloved hands and re-entered without sanitizing the gloves.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. The firm produced hazardous drugs without adequate separation and cleaning to prevent cross-contamination.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  6. Media fill tests (process simulations) were not run under the most challenging conditions, and smoke studies did not show proper airflow.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]

What FDA wants

FDA asks the firm to notify the office in writing within 15 working days of receipt of steps taken to address the violations, with explanations and supporting documents. FDA also strongly recommends a comprehensive assessment of sterile operations with a third-party expert.

Who should pay attention

  • patients who receive compounded sterile drugs
  • clinics and hospitals that buy compounded sterile products
  • pharmacies and compounders with sterile operations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk